Table 2.

Study characteristics of 788 more aggressive prostate cancer patients according to progression status

Prostate cancerNo prostate cancer
progressionprogression
No. (%)228 (28.9)560 (71.1)
Age, mean (SD)62.4 (6.9)63.7 (7.7)
Race/ethnicity, n (%)
    White162 (71.1)393 (70.2)
    African-American66 (29.0)167 (29.8)
Gleason score, n (%)
    ≤629 (12.7)149 (26.6)
    3 + 488 (38.6)240 (42.9)
    4 + 3 or >8111 (48.7)171 (30.5)
Tumor stage, n (%)*
    T166 (29.0)221 (39.5)
    T2a-T2b39 (17.1)87 (15.6)
    T2c66 (29.0)215 (38.5)
    ≥T357 (25.0)36 (6.4)
PSA at diagnosis; ng/mL, mean (±SD)12.7 (±24.3)8.6 (±7.0)
Treatment
    Radical prostatectomy170 (74.6)343 (61.3)
    Radiotherapy58 (25.4)217 (38.8)
  • *Does not add to 788 due to missing information.